China’s Drug Risk Control To Focus On APIs, Excipients, Packaging
This article was originally published in PharmAsia News
Executive Summary
China’s State FDA Deputy Commissioner Wu Zhen sets out drug safety regulation focuses for 2013 at a recent conference